Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS)

Historical Holders from Q1 2018 to Q3 2025

Symbol: RCUS on NYSE
Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 105,670,220
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 100,610,225
Holdings value: $1,368,169,061
% of all portfolios: 0.001%
Number of holders: 185
Number of buys: 91
Number of sells: -86
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
GILEAD SCIENCES, INC.	25.6%	-13.7%	$427,376,736		31,424,760	0%	GILEAD SCIENCES, INC.	03 Nov 2025
BlackRock, Inc.	9.4%		$82,809,606		9,977,061		BlackRock, Inc.	31 Mar 2025
Point72 Asset Management, L.P.	4.1%	-28%	$58,921,714	-$20,381,232	4,332,479	-25.7%	Point72 Asset Management, L.P.	30 Sep 2025

Institutional Holders of Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	100,610,225	$1,368,169,061	+$17,186,644	$1,989,680	$44,946,640	$13.6	185
2025 Q2	99,735,332	$811,386,525	+$23,005,595	$1,357,752	$25,916,520	$8.14	181
2025 Q1	97,195,653	$762,981,433	+$76,941,552	$912,955	$907,460	$7.85	183
2024 Q4	83,908,968	$1,249,338,646	-$21,214,675	$2,050,353	$4,294,276	$14.89	185
2024 Q3	53,324,923	$815,463,718	+$21,618,657	$2,158,948	$3,614,556	$15.29	184
2024 Q2	51,955,193	$791,285,512	-$15,709,425	$2,301,253	$2,631,744	$15.23	191
2024 Q1	52,828,671	$997,275,069	+$741,376	$2,809,584	$3,846,096	$18.88	169
2023 Q4	52,818,611	$1,008,878,346	-$1,266,933	$4,213,460	$12,688,130	$19.1	181
2023 Q3	52,811,112	$947,947,087	-$30,726,648	$10,908,215	$9,903,015	$17.95	184
2023 Q2	54,702,646	$1,110,123,478	-$11,409,103	$15,167,508	$24,644,154	$20.31	177
2023 Q1	55,490,875	$1,012,137,432	+$17,396,401	$7,075,296	$9,489,872	$18.24	177
2022 Q4	53,808,832	$1,112,728,096	+$17,661,819	$13,555,996	$6,313,804	$20.68	199
2022 Q3	52,505,739	$1,373,608,654	-$54,087	$4,371,000	$4,036,000	$26.16	171
2022 Q2	52,444,913	$1,329,092,467	-$15,970,235	$19,802,000	$9,639,000	$25.34	162
2022 Q1	50,609,470	$1,598,261,880	-$43,817,366	$10,756,000	$20,247,000	$31.56	146
2021 Q4	50,826,972	$2,056,609,533	+$107,109,155	$9,257,000	$5,799,000	$40.47	136
2021 Q3	48,251,727	$1,682,950,642	+$59,932,851	$1,252,000	$4,802,000	$34.87	127
2021 Q2	45,147,112	$1,239,729,813	+$11,589,356	$13,580,000	$3,395,000	$27.46	125
2021 Q1	44,736,322	$1,254,917,338	+$7,899,154	$12,299,000	$3,140,000	$28.08	143
2020 Q4	44,575,673	$1,157,187,273	+$10,417,742	$4,218,000	$6,765,000	$25.96	143
2020 Q3	44,391,126	$760,991,949	+$17,571,170	$1,117,000	$7,148,000	$17.14	127
2020 Q2	41,840,912	$1,034,233,021	+$380,488,277	$661,000	$3,293,000	$24.74	138
2020 Q1	26,992,583	$374,653,368	-$448,171			$13.88	92
2019 Q4	23,560,774	$237,962,351	-$3,030,738			$10.1	74
2019 Q3	25,809,690	$234,896,496	-$672,043			$9.1	73
2019 Q2	26,440,928	$210,047,107	+$6,023,856			$7.95	76
2019 Q1	25,799,127	$322,227,437	-$12,715,178			$12.49	63
2018 Q4	26,918,679	$289,911,060	-$4,742,182			$10.77	66
2018 Q3	22,437,315	$312,774,356	+$950,561			$13.94	56
2018 Q2	22,392,855	$274,091,081	+$31,576,470			$12.24	61
2018 Q1	16,255,471	$250,516,107	+$250,516,106			$15.44	55